Zogenix (ZGNX) Tops Q2 EPS by 4c

Zogenix (NASDAQ: ZGNX) reported Q2 EPS of ($0.96), $0.04 better than the analyst estimate of ($1.00).

“In June, we were thrilled to receive U.S. Food and Drug Administration (FDA) approval for FINTEPLA® for the treatment of seizures associated with Dravet syndrome,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “This was a significant milestone for Zogenix and those in the Dravet community seeking effective new treatment options. Last week, we commenced the commercial launch of FINTEPLA in the United States and are very pleased with our early progress. More than 230 U.S. healthcare providers have successfully completed the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) certification required to begin prescribing of FINTEPLA.”

“Despite the global pandemic, we have been able to continue advancing projects that will further support our growth as a commercial-stage rare disease company,” continued Dr. Farr. “We recently held positive meetings with the FDA to discuss the remaining development path to support a planned New Drug Application (NDA) submission for MT1621 for the treatment of thymidine kinase 2 deficiency. In addition, a meeting with the FDA has been scheduled in September to discuss next steps for our supplemental NDA (sNDA) for FINTEPLA in Lennox-Gastaut syndrome (LGS), another difficult-to-treat childhood onset epilepsy.”

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Shopify board member resigns to join U.S. Department of Commerce
• Six Flags names Mark Pauls as chief operating officer